

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**FIRST QUARTER**  
**2009**

**EQUITY INCOME FROM AFFILIATES (millions of dollars)**

	1Q `09	1Q `08
MERCK / SCHERING-PLOUGH	\$ 290.9	\$ 392.8
ASTRAZENECA LP	168.3	131.1
Other <sup>(1)</sup>	126.6	128.2
<b>TOTAL</b>	<b>\$ 585.8</b>	<b>\$ 652.1</b>

<sup>(1)</sup> Primarily reflects results for Merial Limited, Sanofi Pasteur MSD and Johnson & Johnson<sup>o</sup>Merck Consumer Pharmaceuticals.

**JOINT VENTURE SALES DETAIL (millions of dollars)**

All sales reported here are end-market JV sales, presented on a "NET" basis.

<b>Merial</b>	1Q `09	1Q `08
FRONTLINE, other fipronil	\$ 306.9	\$ 341.6
BIOLOGICALS	171.9	174.4
IVOMEK, HEARTGARD, other avermectins	134.7	146.1
Other Animal Health	70.6	71.5
<b>TOTAL MERIAL SALES</b>	<b>\$ 684.1</b>	<b>\$ 733.6</b>

<b>Sanofi Pasteur-MSD</b>	1Q `09	1Q `08
GARDASIL	\$ 164.1	\$ 239.8
OTHER VIRAL VACCINES	25.4	22.7
HEPATITIS VACCINES	13.4	18.0
ROTATEQ	8.7	6.0
Other Vaccines	131.7	124.9
<b>TOTAL SANOFI PASTEUR-MSD SALES</b>	<b>\$ 343.3</b>	<b>\$ 411.4</b>

<b>Merck / Schering-Plough Collaboration</b>	1Q `09	1Q `08
VYTORIN	\$ 466.0	\$ 651.2
ZETIA	479.3	581.7
<b>TOTAL MERCK / SCHERING-PLOUGH SALES</b>	<b>\$ 945.3</b>	<b>\$ 1,232.9</b>

**OTHER (INCOME) EXPENSE, NET (millions of dollars)**

	1Q `09	1Q `08
INTEREST INCOME	\$ (96.3)	\$ (169.5)
INTEREST EXPENSE	60.7	72.6
EXCHANGE LOSSES	16.5	12.6
Other, net <sup>(1)</sup>	(48.1)	(2,124.9)
<b>TOTAL</b>	<b>\$ (67.2)</b>	<b>\$ (2,209.2)</b>

<sup>(1)</sup> Other, net in the first quarter of 2008 primarily reflects a \$2.2 billion gain on distribution from AstraZeneca LP.

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**FIRST QUARTER**  
**2009**

**NET PRODUCT SALES DETAIL (millions of dollars)**

PRODUCT	1Q '09 vs. 1Q '08					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
COZAAR / HYZAAR	-1%	839	2%	304	-2%	535
JANUVIA	51%	411	38%	313	*	98
JANUMET	*	128	83%	100	*	28
SINGULAIR	-4%	1,057	-4%	682	-4%	375
Vaccines:						
GARDASIL	-33%	262	-39%	179	-14%	83
ROTATEQ	-29%	134	-31%	124	-7%	10
ZOSTAVAX	2%	75	2%	75	N/A	-
OTHER VIRAL VACCINES <sup>(1)</sup>	12%	252	16%	235	-28%	17
HEPATITIS VACCINES <sup>(2)</sup>	2%	35	16%	29	-36%	6
OTHER VACCINES <sup>(3)</sup>	-23%	56	2%	30	-41%	26
Other Reported Products:						
ARCOXIA	-13%	81	N/A	-	-13%	81
CANCIDAS	-7%	139	-37%	19	1%	120
COSOPT / TRUSOPT	-40%	121	-83%	14	-11%	107
CRIVAN / STOCRIN	-35%	49	-23%	3	-35%	46
EMEND	16%	69	9%	44	30%	25
FOSAMAX	-44%	261	-80%	41	-18%	220
INVANZ	11%	62	17%	33	5%	29
ISENTRESS	*	148	*	75	*	73
MAXALT	10%	133	18%	92	-5%	41
PRIMAXIN	-19%	165	-41%	30	-11%	134
PROPECIA	-2%	103	-3%	36	-2%	67
PROSCAR	-15%	72	-54%	1	-14%	71
TIMOPTIC / TIMOPTIC XE	-5%	28	-58%	1	-1%	27
VASOTEC / VASERETIC	-19%	77	N/A	-	-19%	77
ZOCOR	-23%	137	-70%	8	-15%	129
ZOLINZA	15%	5	16%	4	-6%	-

\* 100% or over

N/A - Not Applicable

<sup>(1)</sup> - Includes ProQuad, M-M-R II and Varivax.

<sup>(2)</sup> - Includes Recombivax and Vaqta

<sup>(3)</sup> - Includes Pneumovax, Comvax and Pedvaxhib

**TOTAL SALES: VOLUME, PRICE, EXCHANGE**

	1Q '09	% CHG	VOL	PX	FX
<b>TOTAL PHARMACEUTICAL SALES</b>	\$ 5,385	-8%	-6	1	-3
U.S. (\$ MM)	2,957	-10%	-15	4	N/A
Foreign (\$ MM)	2,428	-4%	6	-2	-8